Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 7/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EED | O75530 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363893 | 1.00 | CTSC (0.39) | CTSCPRMT5WDR77L3MBTL1EED | |
| SCHEMBL5770303 | 1.00 | CTSC (0.39) | CTSCPRMT5WDR77L3MBTL1EED | |
| SCHEMBL5697197 | 0.81 | CTSC (0.45) | CTSCPRMT5WDR77L3MBTL1EED | |
| SCHEMBL6364103 | 0.81 | CTSC (0.45) | CTSCPRMT5WDR77L3MBTL1EED | |
| SCHEMBL5697201 | 0.81 | CTSC (0.45) | CTSCPRMT5WDR77L3MBTL1EED | |
| Hydrochloric Acid SCHEMBL6367895 | 0.79 | CTSC (0.44) | CTSCPRMT5WDR77L3MBTL1EED | |
| Hydrochloric Acid SCHEMBL6364625 | 0.79 | CTSC (0.44) | CTSCPRMT5WDR77L3MBTL1EED | |
| Hydrochloric Acid SCHEMBL5768201 | 0.79 | CTSC (0.44) | CTSCPRMT5WDR77L3MBTL1EED | |
| Hydrochloric Acid SCHEMBL5768200 | 0.79 | CTSC (0.44) | CTSCPRMT5WDR77L3MBTL1EED | |
| SCHEMBL30468231 | 0.71 | CTSC (0.36) | CTSCPRMT5WDR77L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615885-A1 | B -FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092132-A1 | [B]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | claimed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | CTSC 487/4885PRMT5 2142/4885WDR77 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.